GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Clinical Trials
764
Trial Phases
5 Phases
Drug Approvals
40
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (640 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT07051993
- Locations
- 🇬🇧
Fortrea Leeds CRU, Leeds, United Kingdom
A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT07025577
- Locations
- 🇺🇸
Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States
🇺🇸Fortrea Clinical Research Unit - Dallas, Dallas, Texas, United States
🇺🇸Fortrea Clinical Research Unit Inc. - Madison, Madison, Wisconsin, United States
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT07008378
- Locations
- 🇺🇸
UC Irvine, Sue & Bill Gross Stem Cell Research Center, Irvine, California, United States
🇺🇸UC San Diego, Altman Clinical and Translational Research Institute, La Jolla, California, United States
🇺🇸University of South Florida, Tampa, Florida, United States
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2025-05-22
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT06984341
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: RO7837195Drug: RO7837195 Matched Placebo
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT06979336
- Prev
- 1
- 2
- 3
- 4
- 5
- 100
- Next
News
Tryptase Inhibitor Fails to Meet Primary Endpoint in Asthma Exacerbation Trial
A Phase 2a clinical trial of MTPS9579A, an anti-tryptase antibody, did not significantly reduce the time to first asthma exacerbation event compared to placebo.